NCT05131997View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

PHASE3CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

June 8, 2022

Study Completion Date

June 8, 2022

Conditions
Primary Hypercholesterolemia
Interventions
DRUG

AD-221

PO, Once daily(QD), 8 weeks

DRUG

AD-221A

PO, Once daily(QD), 8 weeks

DRUG

AD-221B

PO, Once daily(QD), 8 weeks

DRUG

AD-221C

PO, Once daily(QD), 8 weeks

Trial Locations (1)

03722

Yonsei University Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT05131997 - A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A | Biotech Hunter | Biotech Hunter